AAA to conduct pivotal study of Lutate in neuroendocrine tumours
This article was originally published in Clinica
Advanced Accelerator Applications (AAA) is to begin a pivotal Phase III trial of Lutate, its radiolabelled peptide anticancer compound. The 300-patient multicentre trial will assess Lutate in the treatment of patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Saint Genis Pouilly, France-based AAA has commissioned Pierrel Research International to conduct the study. Lutate is a somatostatine analogue labelled with Lutetium-177. It selectively targets somatostatine receptors, which are overexpressed in tumour cells; the radiation then destroys the cells. Lutate has FDA and EMEA Orphan Drug status, giving it protection from competition for seven years in the US and 10 years in Europe following approval. Sales of the compound could begin in 2015 (www.clinica.co.uk, 6 April 2011).
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.